製藥、生物技術、醫療器材和診斷領域的資產購買交易（2016-2024）

本報告詳細了解並分析了公司如何以及為何進行業務、產品、技術和特許權使用費等資產購買交易。

本報告提供了各方之間公佈的資產購買交易的付款條件。這些資料提供了有關支付條款和其他交易條款的寶貴見解。

本報告重點在於可供購買的四種主要資產類型：

• 企業資產
• 產品資產
• 特許權使用費資產
• 技術資產
• 了解潛在合作夥伴談判條款的彈性，並深入了解談判過程，以了解條款談判期間的預期結果。許多小型企業會要求提供付款條件的詳細信息，但在包括付款方式和權利如何轉讓時，細節是關鍵。
• 本報告提供了自2016年以來宣布的資產購買交易的完整列表，目前協議案件/合作夥伴資料庫中記錄的內容，並包括可用的財務條款，以及公司及其合作夥伴向證券交易委員會提交的實際許可協議文件的線上副本的連結。

主要優點

本報告為讀者提供了以下主要好處：

• 了解2016年以來的交易完成趨勢
• 查看資產購買交易
• 基準分析：確定交易的市場價值
• 財務狀況
• 交易清單：依公司名稱（A-Z）、依治療領域、依技術類型
• 主要交易（金額基礎）
• 最活躍的交易者
• 每筆交易的資產識別和交易條件
• 取得合約文件：深入了解交易結構
• 實質審查：評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

調查範圍

• 本報告目的是詳細了解全球領先的生物製藥公司的資產購買趨勢和交易結構。

此報告包含以下資訊：

• 生命科學產業資產購買交易的趨勢
• 資產購買交易結構：概覽
• 藥品、生物技術、醫療器材和診斷領域的資產購買交易記錄列表
• 重大資產購買交易（價值基礎）
• 最活躍的資產購買交易商
• 資產購買的主要合作夥伴資源

此報告按以下順序列出了可用資訊的交易：

• 依公司名稱（A-Z）
• 依交易金額
• 依治療領域
• 依技術種類
• 每個交易標題都透過網路連結連結到實際交易記錄的線上版本。
• 此報告提供對資產購買交易的可用合約文件的全面存取。

透過分析合約協議，實質審查可以：

• 授予和選擇了哪些權利？
• 合約授予了哪些權利？
• 授予哪些專有權？
• 合約的付款結構是怎樣的？
• 如何審核銷售和付款？
• 合約期限是多久？
• 合約的主要條款是如何定義的？
• 如何對待和擁有知識產權？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和發布？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已商定何種類型的分授權或分包條款？
• 公司需要哪些樣板條款？
• 哪些樣板條款會根據合作夥伴和交易類型的不同而有所不同？
• 每家公司都主張合約法中的哪一個管轄權？

目錄

執行摘要

第1章 簡介

第2章 資產購買趨勢

• 簡介
• 資產購買的定義
• 資產購買趨勢（2016年以來）
  • 資產購買交易：依年份（2016-2024年）
  • 資產購買交易：依發展階段劃分（2016-2024年）
  • 資產購買交易：依產業分類（2016-2024年）
  • 資產購買交易：依治療領域分類（2016-2024年）
  • 資產購買交易：依技術類型劃分（2016-2024年）
  • 資產購買交易：針對最活躍的公司（2016-2024年）
• 簽訂資產購買協議的原因
  • 企業資產
  • 產品資產
  • 特許權使用費資產
  • 技術資產
• 未來資產購買交易

第3章 資產購買交易結構概論

• 簡介
• 資產購買結構

第4章 重大資產購買交易

• 簡介
• 主要資產購買交易（金額基礎）

第5章 最活躍資產購買者前25名

• 簡介
• 前 25 名最活躍資產購買者（交易公司）

第6章 資產購買交易清單（含合約明細）

• 簡介
• 資產購買交易協議（2016-2024年）
• 交易列表
• 交易清單：資產購買交易，依公司名稱（A-Z）
• 交易清單：資產購買交易，依治療領域
• 交易清單：資產購買交易，依技術類型
• 關於生物製藥研究股份有限公司
• 目前的合作關係
• 當前合約
• Current Partnering 發布的最新報告標題

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
• Chapter 3 provides an overview of the structure of asset purchase deals.
• Chapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
• Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
• The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
• The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.
• In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

Key benefits

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse asset purchase deals
• Benchmark analysis - identify market value of transactions
• Financials - headline, upfront, milestone, royalty rates
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics includes:

• Trends in asset purchase dealmaking in the life sciences industry
• Overview of asset purchase deal structure
• Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
• The leading asset purchase deals by value
• Most active asset purchase dealmakers
• The leading asset purchase partnering resources

In Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.
• Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2016
  • 2.3.1. Asset purchase dealmaking by year, 2016-2024
  • 2.3.2. Asset purchase dealmaking by phase of development, 2016-2024
  • 2.3.3. Asset purchase dealmaking by industry sector, 2016-2024
  • 2.3.4. Asset purchase dealmaking by therapy area, 2016-2024
  • 2.3.5. Asset purchase dealmaking by technology type, 2016-2024
  • 2.3.6. Asset purchase dealmaking by most active company, 2016-2024
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts 2016-2024
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements, 2016-2024
• Figure 3: Asset purchase deals signed at each phase of development, 2016-2024
• Figure 4: Asset purchase deals by industry sector, 2016-2024
• Figure 5: Asset purchase deals by therapy area, 2016-2024
• Figure 6: Asset purchase deals by technology type, 2016-2024
• Figure 7: Top 25 most active asset purchase dealmakers, 2016-2024
• Figure 8: Top asset purchase deals by value, 2016-2024
• Figure 9: Most active asset purchase dealmakers, 2016-2024